CCO Think Tank: Emerging HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

Clinical commentary, downloadable slides, and on-demand text modules on biomarker testing, recent data, and clinical management of adverse events associated with antibody–drug conjugate therapies in patients with genitourinary, gastrointestinal, and gynecologic cancers.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.